And despite recent reports of a potential federal pilot program to extend coverage of GLP-1 obesity drugs under Medicaid and Medicare, all state Medicaid programs are likely to be under pressure due to steep spending cuts in the budget reconciliation package recently signed into law by President Donald Trump
Challenges and Future Directions While the preliminary results of 5-Amino-1MQ are promising, its essential to acknowledge that the journey from preclinical studies to human applications is complex
1 Thus, numerous studies have used biotechnology to extend the half-life of GLP-1 RAs, with strategies including amino acid sequence substitution, fatty acid conjugation with a linker, fusion of albumin or the IgG fragment crystallizable (Fc) region (Figure 1)
Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes
398 Validation in 2D and 3D tumor models further supports the rational optimization of nanomedicines to reverse MDR in physiologically relevant settings
Integrating advanced molecular profiling and multiomics analyses offers a comprehensive understanding of DR pathogenesis, paving the way for innovative interventions to mitigate disease progression